60岁以上肝细胞癌患者微波消融:合并症对生存的影响
多中心回顾性队列纳入530例60岁及以上BCLC A或B期肝细胞癌患者,按改良Charlson合并症指数(mCCI)分为0、1、≥2组,评估超声引导微波消融后总生存、无进展生存和癌症相关死亡。重叠加权Cox和Fine-Gray模型显示mCCI与OS、PFS及癌症相关死亡均无显著关联,敏感性分析结果一致。
要点
- 老年HCC患者行超声引导MWA后,mCCI合并症负担与总生存无显著关联。
- mCCI与无进展生存及癌症相关死亡同样无显著关联,竞争风险模型验证。
- 对 selected 老年HCC患者,合并症负担不应单独作为MWA排除标准。
诊断标准与关键数值
- 合并症分组采用改良Charlson合并症指数(mCCI):0、1、≥2三组。
- 总体队列530例中,mCCI 0组301例、mCCI 1组107例、mCCI ≥2组122例。
- 重叠加权后标准化均数差均低于0.10。
- mCCI与OS无总体关联(全局p=0.103),与PFS无总体关联(全局p=0.973)。
- 153例死亡中癌症相关死亡111例、非癌死亡42例;mCCI与癌症相关死亡无关联(全局p=0.750)。
临床应用与阅片要点
- 对60岁及以上BCLC A或B期HCC患者评估MWA适应证时,合并症负担(mCCI)不应单独作为排除依据。
- 阅片报告可关注肿瘤分期(BCLC A/B)及消融靶区评估,合并症信息供临床综合判断。
- 老年患者治疗决策需结合肿瘤负荷、肝功能及合并症多维度评估,而非仅凭mCCI分层。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 研究对象为经选择的老年HCC患者,结论外推需谨慎。
- 原文未报告具体随访时间、消融技术参数及多中心具体数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To examine whether comorbidity burden, categorized using the modified Charlson Comorbidity Index (mCCI), was associated with overall survival (OS), progression-free survival (PFS), and cancer-related death after ultrasound-guided microwave ablation (MWA) in older patients with hepatocellular carcinoma (HCC).
METHODS: This multicenter retrospective cohort included 530 patients aged 60 years or older with Barcelona Clinic Liver Cancer stage A or B HCC. Patients were classified as mCCI 0, 1, or ≥ 2. Generalized propensity scores were estimated using multinomial logistic regression. Overlap-weighted Cox models evaluated OS and PFS, with stabilized inverse probability of treatment weighting and bootstrap validation as sensitivity analyses. Fine-Gray models evaluated cancer-related death, with noncancer death as a competing event.
RESULTS: Overall, 301 patients had mCCI 0, 107 had mCCI 1, and 122 had mCCI ≥ 2. Overlap weighting achieved standardized mean differences below 0.10. No overall association was observed between mCCI and OS (global p = 0.103) or PFS (global p = 0.973). Among 153 deaths, 111 were cancer related and 42 were noncancer deaths. Fine-Gray analysis showed no association between mCCI and cancer-related death (global p = 0.750). Sensitivity analyses were consistent.
CONCLUSION: mCCI was not robustly associated with OS, PFS, or cancer-related death among selected older patients with HCC treated with MWA.
引用
- He L, Qiao Y, Chen S, et al. Microwave Ablation for Hepatocellular Carcinoma in Patients Older Than 60 Years: Impact of Comorbidities on Survival. Ultrasound Med Biol. 2026. PMID: 42957516. doi:10.1016/j.ultrasmedbio.2026.09.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。